Overview: Managing Migraine in Adults
The full newsletter "Managing Migraine in Adults", prescribing information and CME self-assessment are free for both AMA members and non-members.
Migraine affects approximately 12% of the U.S. adult population and is associated with diminished quality of life, significant functional impairment, curtailed activities, and lost days from work and school. Migraine is a chronic disorder rather than a series of recurrent headache attacks, and can be associated with significant physical and psychiatric comorbidities. Migraine is underdiagnosed, undertreated and often misdiagnosed.
After establishing a migraine diagnosis, management should include avoidance of potential triggers and risk factors (if identifiable), including avoidance of excessive caffeine intake; lifestyle modification that includes regular exercise, regular sleep and wake schedules, and regular meals; acute therapy and prophylactic therapy, if indicated, and regularly scheduled medical follow-up.
The American Academy of Neurology (AAN) guidelines for migraine recommend migraine-specific agents (triptans, dihydroergotamine) in individuals with moderate or severe migraine or in those whose mild-to-moderate migraine episodes do not respond to OTC analgesics. While the use of triptans is the dominant therapeutic intervention, national patient claims data provide an interesting and surprising profile on the relative use of different agents for the acute treatment of migraine.
In "Management of Migraine in Adults" physicians will learn to:
- Apply evidence-based approaches in the diagnosis and management of migraine headache
- Compare current approach to treatment at the state and national levels with professional guideline recommendations.
The full newsletter will provide you further insight into the use of migraine-specific drugs for migraine headache.
Read the full newsletter "Managing Migraine in Adults" and learn how to receive CME credit. Newsletters are available to all physicians, not just AMA members.